CEA Grants Roche License to Patent that Covers a Process for Synthesis of dsRNA
News Apr 13, 2006
The CEA has announced that its life science division has granted Roche Diagnostics GmbH, (Mannheim, Germany) a non-exclusive license under the patent family EP10618966.
This license concerns some RNAi products that Roche Diagnostics GmbH supplies to its customers in the research reagent field.
This patent family, owned solely by the CEA, covers a process for an enzymatic synthesis of double-stranded RNA based on the transcription of a double-stranded DNA template.
Double-stranded RNA triggers different types of gene silencing named RNA silencing or RNA interference. The application of RNA interference in mammals has the potential to allow therapeutic gene silencing.
Schizophrenics' Blood Contains RNA From More MicrobesNews
The blood of schizophrenia patients features genetic material from more types of microorganisms than that of people without the debilitating mental illness, research at Oregon State University has found. What’s not known is whether that’s a cause or effect of the severe, chronic condition that strikes about one person in 100.READ MORE
Faulty Gene Leads to Alcohol-Induced Heart FailureNews
A faulty gene interacts with alcohol to accelerate heart failure in susceptible patients, a study suggests. This dangerous interaction can occur even when only moderate amounts of alcohol have been consumed.READ MORE
Genetic Diversity Helps Protect Against DiseaseNews
Why do populations have genetic diversity when 'Survival of the Fittest' suggests that only one gene pool should thrive? It's a question that is hard to answer experimentally. A new study looking at evolutionary change in real time in tiny fungal parasites may provide a solution.